Organization
Thoracic and GI Malignancies Branch
4 abstracts
Abstract
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Princess Margaret Cancer Centre, University of Toronto,
Abstract
Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.Org: National Cancer Insititute, Developmental Therapeutics Branch, Nihon Medi-Physics, Epidemiology and Biostatistics, Thoracic and GI Malignancies Branch,
Abstract
A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Laboratory of Pathology, NCI, NIH, Bethesda, MD,
Abstract
Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC).Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Teiko Bio,